Opko Chile S.a.,

Opko Chile S.A. is a Chilean pharmaceutical company specializing in the importation, commercialization, and distribution of finished pharmaceutical formulations. Established on October 7, 2009, it operates as a subsidiary of OPKO Health, Inc., a U.S.-based multinational pharmaceutical and diagnostics company headquartered in Miami, Florida. The acquisition of Pharma Genexx S.A. by OPKO Health marked the inception of Opko Chile S.A., expanding OPKO's presence in the Latin American market.

Headquartered in Santiago, Chile, Opko Chile S.A. focuses on the development, production, and commercialization of pharmaceutical products and medical supplies. Its product portfolio encompasses a wide range of therapeutic areas, including cardiovascular, gastrointestinal, respiratory, and over-the-counter (OTC) products. The company serves both public and private institutions, including government entities like the National Health Service (CENABAST), independent pharmacies, and major pharmacy chains, ensuring nationwide distribution through its dedicated sales force. (getonbrd.cl)

Opko Chile S.A. maintains its primary office at Agustinas 640, 10th floor, in the Metropolitan Region of Santiago. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company is known to have a nationwide distribution network. This extensive coverage enables Opko Chile S.A. to effectively supply pharmaceutical products across Chile, catering to both urban and rural regions. The company's logistics infrastructure is designed to ensure timely and efficient delivery of products to various stakeholders, including hospitals, pharmacies, and government institutions. (getonbrd.cl)

In Chile's pharmaceutical supply chain, Opko Chile S.A. functions primarily as an importer and distributor of finished pharmaceutical formulations. The company sources a diverse range of products from international suppliers, including Indian manufacturers, and is responsible for their commercialization and distribution within the Chilean market. By importing and distributing these products, Opko Chile S.A. plays a crucial role in ensuring the availability of essential medications across the country, thereby contributing to the overall healthcare infrastructure. (getonbrd.cl)

Opko Chile S.A. demonstrates a significant concentration in its sourcing strategy, with a total import value of $11.2 million USD from India over 295 shipments. The top five imported products—Losartan, Enalapril, Lactulose, Domperidone, and Ambroxol—account for 96.8% of the total import value, indicating a high degree of portfolio concentration. This sourcing pattern suggests a strategic focus on specific therapeutic areas, particularly cardiovascular and gastrointestinal treatments. The reliance on a limited number of products may streamline operations and strengthen supplier relationships but also exposes the company to risks associated with market fluctuations and regulatory changes affecting these specific products.

The shipment data reveals a stable relationship with Indian suppliers, with the top supplier, EMIL Pharmaceutical Industries Private Limited, accounting for 53.6% of the total import value. This indicates a strong and ongoing partnership, which can lead to favorable terms and consistent product quality. However, the high concentration on a few suppliers and products may pose challenges if there are disruptions in supply chains or changes in regulatory environments.

Opko Chile S.A.'s supply chain resilience is closely tied to its sourcing strategy from Indian suppliers. The company's dependence on a limited number of suppliers and products suggests a streamlined procurement process but also highlights potential vulnerabilities. The absence of publicly available information regarding backup suppliers and the diversity of formulations imported indicates a need for strategic planning to mitigate risks associated with supply chain disruptions. Ensuring compliance with international Good Manufacturing Practice (GMP) standards and maintaining strong relationships with key suppliers are essential for sustaining supply chain stability.

The concentrated sourcing pattern of Opko Chile S.A. positions the company to leverage strong relationships with key suppliers, potentially securing favorable terms and consistent product quality. However, this strategy also exposes the company to risks related to supply chain disruptions, regulatory changes, and market fluctuations affecting the specific products imported. For Indian exporters, understanding Opko Chile S.A.'s focus on cardiovascular and gastrointestinal products presents an opportunity to align their offerings with the company's needs, potentially expanding their market presence in Chile.

In Chile, the regulatory authority responsible for the control of pharmaceutical products, including biologicals and medical devices, is the Public Health Institute (Instituto de Salud Pública, ISP). The ISP operates under the Ministry of Health (MINSAL) and oversees regulations governing the import, clearance, export, production, and manufacturing of pharmaceutical products and medical devices. The Ministry of Health is responsible for defining and controlling these regulations, ensuring that imported pharmaceutical products meet the required standards for safety, efficacy, and quality. (britcham.cl)

Key legislation governing pharmaceutical imports into Chile includes the Health Code (Código Sanitario) and the Pharmaceutical Regulations (Reglamento Sanitario de los Alimentos). These regulations outline the requirements for product registration, labeling, advertising, and distribution. The ISP is responsible for enforcing these regulations, ensuring that all pharmaceutical products imported into Chile comply with the established standards. (britcham.cl)

Import licensing requirements in Chile stipulate that pharmaceutical products must be registered with the ISP before they can be imported and marketed. The registration process involves submitting detailed information about the product, including its composition, intended use, packaging, labeling, and manufacturer information. Importers must also comply with specific requirements regarding the storage, transportation, and distribution of pharmaceutical products to ensure their quality, safety, and efficacy.

The ISP recognizes Good Manufacturing Practice (GMP) certificates from various international organizations, including the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Pharmaceutical products imported into Chile must be manufactured in facilities that adhere to these recognized GMP standards. Additionally, importers must obtain wholesale distribution authorization from the ISP, which involves demonstrating compliance with regulatory requirements and maintaining appropriate facilities for the storage and distribution of pharmaceutical products.

Imported pharmaceutical products must undergo batch testing to ensure they meet the required quality standards. Stability studies are also conducted to determine the product's shelf life and ensure its efficacy over time. Labeling requirements mandate that all information, including ingredients, manufacturing and expiration dates, and the name of the producer or importer, be provided in Spanish. Measurements must be in the metric system, and the country of origin must be clearly indicated.

Serialization mandates may apply to certain pharmaceutical products to enhance traceability and prevent counterfeit products from entering the market. These requirements are part of Chile's efforts to ensure the safety and integrity of pharmaceutical products available to consumers.

Between 2024 and 2026, Chile has implemented policy changes affecting pharmaceutical imports, including the incorporation of new legislation known as Ley de Fármacos II. This legislation further restricts promotional labeling on health products, aiming to ensure that advertising and labeling are consistent with the information contained in the product's sanitary register. The ISP is responsible for enforcing these regulations, which impact how pharmaceutical products are marketed and labeled in Chile. (britcham.cl)

Opko Chile S.A.'s product category focus on cardiovascular (78.2%), gastrointestinal (14.3%), and respiratory & OTC (6.6%) products aligns with the therapeutic areas of its top imported products: Losartan, Enalapril, Lactulose, Domperidone, and Ambroxol. This strategic focus is driven by market demand for treatments in these areas, addressing prevalent health conditions in Chile. By concentrating on these therapeutic categories, Opko Chile S.A. aims to meet the needs of both public and private healthcare sectors, ensuring the availability of essential medications.

Opko Chile S.A. primarily sources generic pharmaceutical products from India, with a total import value of $11.2 million USD over 295 shipments. The company's sourcing strategy emphasizes finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows Opko Chile S.A. to offer a diverse range of products to the Chilean market, catering to various therapeutic needs. India's established pharmaceutical manufacturing industry, known for its adherence to international GMP standards, makes it a reliable source for these products.

Based on its product mix, Opko Chile S.A. serves multiple segments of the Chilean pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's extensive distribution network and diverse product portfolio enable it to cater